Dynavax to Present at the RBC Capital Markets Global Healthcare Conference

BERKELEY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation DVAX announced today that Eddie Gray, Dynavax's chief executive officer, will participate in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference in New York City. The presentation will be webcast live and will occur on Wednesday, February 21, 2018 at 1:35 p.m. ET.

The live or replayed versions of the webcast will be available by visiting the "Investors" section of the Dynavax website at www.dynavax.com.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company's first commercial product, HEPLISAV-Bâ„¢ [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.

Contact:

David Burke

Director, Investor Relations & Corporate Communications

510.665.7269

dburke@dynavax.com 

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!